Codexis, Inc.
NASDAQ:CDXSBiotechnology
+$0.02 today
- Market cap
- $126.04M
- Beta
- 2.48
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.35
Volume 1.47M
Average 1.15M
CDXS Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Codexis, Inc.NASDAQ: CDXS
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares grows, but more slowly than its trailing trend
Q1 FY2026 weighted avg shares of 90.77M shares rose 10.1% year over year, behind the +16.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.4% from the prior quarter. Over 3 fiscal years it compounded at +10.1% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +10.1% toward the trailing-twelve-month pace of +16.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 87.14M USD
- Year-over-year change
- +18.7%
- 4-year CAGR
- +7.8%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 87.14M | +18.7% |
| FY2024 | 2024-12-31 | 73.41M | +7.7% |
| FY2023 | 2023-12-31 | 68.13M | +4.3% |
| FY2022 | 2022-12-31 | 65.34M | +1.2% |
| FY2021 | 2021-12-31 | 64.57M | — |
Weighted Avg Shares vs competitors
How CDXS compares with its peers on the latest reported figures
- CDXS's LTM Mar 2026 weighted avg shares of 89.2M shares is the 7th highest of the 10 companies compared; the peer median is 96.61M shares.
- Its year-over-year change of +16.6% is the 7th highest of 10, against a peer median of +52.9%.
- Over three fiscal years its annual growth of +10.1% compares with a peer median of +19.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 322.14M | +52.9% | +22.0% | |
| LTM Mar 2026 | 193.02M | +61.8% | +16.7% | |
| LTM Mar 2026 | 119.25M | +15.1% | +10.0% | |
| LTM Mar 2026 | 100.04M | +230.0% | +40.6% | |
| LTM Mar 2026 | 96.61M | +38.1% | +19.3% | |
| FY2025 | 89.42M | +10.3% | +4.0% | |
| LTM Mar 2026 | 89.2M | +16.6% | +10.1% | |
| LTM Mar 2026 | 43.36M | +56.7% | +56.1% | |
| LTM Mar 2026 | 36.32M | +0.4% | +1.9% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | 32.26M | +85.3% | +76.5% |
| Peer median (excluding CDXS) | 96.61M | +52.9% | +19.3% | |
Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 104.75M | 138.59M | 70.14M | 59.35M | 70.39M |
| Cost of Revenue | 22.21M | 38.03M | 12.81M | 16.29M | 9.34M |
| Gross Profit | 82.55M | 100.56M | 57.33M | 43.06M | 61.05M |
| Gross Margin | 78.8% | 72.6% | 81.7% | 72.6% | 86.7% |
| Research & Development | 55.92M | 80.1M | 58.89M | 46.26M | 52.31M |
| Selling, General & Admin | 49.32M | 52.17M | 53.25M | 55.15M | 47.07M |
| Operating Expenses | 105.24M | 135.44M | 125.4M | 101.58M | 99.38M |
| Depreciation & Amortization | 5.95M | 5.4M | 5.52M | 4.95M | 5.25M |
| EBITDA | (15.14M) | (26.31M) | (49.28M) | (53.41M) | (33.87M) |
| EBITDA Margin | -14.5% | -19.0% | -70.3% | -90.0% | -48.1% |
| Operating Income | (22.7M) | (34.88M) | (68.07M) | (58.52M) | (38.33M) |
| Operating Margin | -21.7% | -25.2% | -97.0% | -98.6% | -54.5% |
| Interest Income | 459K | 1.44M | 4.17M | 3.67M | 2.63M |
| Interest Expense | 0 | 0 | 0 | 0 | 4.81M |
| Other Income / Expenses | 1.61M | 1.57M | (8.1M) | (6.72M) | (5.6M) |
| Income Before Tax | (21.09M) | (33.32M) | (76.17M) | (65.24M) | (43.93M) |
| Pre-Tax Margin | -20.1% | -24.0% | -108.6% | -109.9% | -62.4% |
| Income Tax Expense | 189K | 276K | 69K | 34K | 47K |
| Net Income | (21.28M) | (33.59M) | (76.24M) | (65.28M) | (43.97M) |
| Net Margin | -20.3% | -24.2% | -108.7% | -110.0% | -62.5% |
| EPS (Basic) | (0.33) | (0.51) | (1.12) | (0.89) | (0.50) |
| EPS (Diluted) | (0.33) | (0.51) | (1.12) | (0.89) | (0.50) |
| Weighted Avg Shares | 64.57M | 65.34M | 68.13M | 73.41M | 87.14M |
| Weighted Avg Shares (Diluted) | 64.57M | 65.34M | 68.13M | 73.41M | 87.14M |
Codexis, Inc.
NASDAQ:CDXS
Intrinsic Alpha fair value
Locked
Current Price
$1.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.